newsfilter
← Latest News
Business Wire·

Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living with Dravet